---
title: A critical review of management of allogeneic transplant-eligible adults with
  Ph+ acute lymphoblastic leukaemia
date: '2024-09-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39289867/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240918184842&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Acute lymphoblastic leukaemia (ALL) in 20%-30% of adult patients contains
  the Philadelphia (Ph+) chromosome. Historically, Ph+ ALL denoted a markedly inferior
  outcome and long-term survival in the absence of an allograft was uncommon. However,
  the advent of targeted therapy directed against the BCR::ABL1 fusion protein with
  various tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis, resulting
  in a number of treatment controversies in allograft-eligible patients. Which is
  ...
disable_comments: true
---
Acute lymphoblastic leukaemia (ALL) in 20%-30% of adult patients contains the Philadelphia (Ph+) chromosome. Historically, Ph+ ALL denoted a markedly inferior outcome and long-term survival in the absence of an allograft was uncommon. However, the advent of targeted therapy directed against the BCR::ABL1 fusion protein with various tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis, resulting in a number of treatment controversies in allograft-eligible patients. Which is ...